Information Provided By: 
Fly News Breaks for February 26, 2020
MGNX
Feb 26, 2020 | 06:51 EDT
Citi analyst Yigal Nochomovitz lowered the firm's price target on MacroGenics to $15 from $18 and keeps a Buy rating on the shares. MacroGenics remains under pressure from uncertainty surrounding the company's late-stage pipeline, Nochomovitz tells investors in a research note. While margetuximab's Biologics License Application acceptance was expected, uncertainty on its commercial prospects remain, says the analyst. Nochomovitz, however, believes multiple readouts from the early-stage pipeline should help the stock work in 2020.
News For MGNX From the Last 2 Days
MGNX
Apr 26, 2024 | 10:06 EDT
MGNX
Apr 26, 2024 | 07:26 EDT
B. Riley initiated coverage of MacroGenics with a Buy rating and $25 price target. The analyst views the company's most advanced candidate, vobra duo, as "significantly de-risked" in the ongoing over-enrolled Phase II TAMARACK registration-enabling study, the analyst tells investors in a research note. The firm MacroGenics' fully integrated development and manufacturing capabilities have led to a partnered program portfolio consisting of three FDA-approved medicines and earlier-stage pipeline candidates.
MGNX
Apr 26, 2024 | 07:09 EDT
B. Riley initiated coverage of MacroGenics with a Buy rating and $25 price target.
